An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily.
Phase of Trial: Phase I
Latest Information Update: 01 May 2016
At a glance
- Drugs Fostamatinib (Primary) ; Pioglitazone
- Indications Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 06 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2011 Last checked against ClinicalTrials.gov record.
- 29 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.